Effects of short-term treatment with orlistat on growth hormone/insulin-like growth factor-I axis in obese postmenopausal women

C. Di Somma, A. Rivellese, G. Pizza, L. Patti, A. De Rosa, P. Cipriano, V. Nedi, A. Rossi, G. Lombardi, A. Colao, S. Savastano

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aim: Obesity is associated with an altered GH/IGF-I axis status, accounting for the increased cardiovascular risk in obese subjects with GH deficiency. Aim of this randomized, simple-blind, cross-over study was to verify the effectiveness of a short-term treatment with orlistat in reducing non-esterified fatty acid (NEFA) and influencing the endogenous activity of GH/IGF-I axis in obese subjects. Outcome measures: The primary outcome measures were post-prandial lipemia; GH peak after GHRH+arginine; IGF-I; IGF-binding protein (BP)-3, IGF-I/IGFBP-3 ratio. Secondary outcome measures were insulin resistance (IR) indexes (homeostasis model assessment of insulin resistance and Insulin Sensitivity Index). Study design: Twenty obese post-menopausal women (age: 53.6±6.2; body mass index: 34.1±4.0) were randomized to receive normo-caloric diet plus + orlistat (Roche, UK; 120 mg tid) or normo-caloric diet without the additional treatment. The duration of follow-up was 10 days for each treatment period. Results: Orlistat induced a weight-independent reduction in post-prandial NEFA levels compared with diet alone, with higher GH peak, IGF-I, and IGF-I/IGFBP3 ratio. GH peak was correlated negatively with postprandial NEFA and positively with IGF-I and IGF-4/IGFBP-3 ratio. Conclusions: Orlistat is effective in inducing a weight-independent high-er reduction in post-prandial NEFA levels than dietary treatment alone along with increase in GH peak, IGF-I levels, and IGF-I/IGFBP-3 ratio. These results might add a new potential benefit of orlistat in the management of obese subjects.

Original languageEnglish
Pages (from-to)90-96
Number of pages7
JournalJournal of Endocrinological Investigation
Volume34
Issue number2
Publication statusPublished - Feb 2011

Fingerprint

Insulin-Like Growth Factor I
Growth Hormone
Insulin-Like Growth Factor Binding Protein 3
Fatty Acids
Meals
Insulin Resistance
Therapeutics
Outcome Assessment (Health Care)
Diet
orlistat
Hyperlipidemias
Cross-Over Studies
Arginine
Weight Loss
Body Mass Index
Homeostasis
Obesity
Weights and Measures

Keywords

  • GH/IGHF-I axis
  • Insulin sensitivity
  • Obesity
  • Orlistat
  • Post-prandial lipid profile

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Effects of short-term treatment with orlistat on growth hormone/insulin-like growth factor-I axis in obese postmenopausal women. / Di Somma, C.; Rivellese, A.; Pizza, G.; Patti, L.; De Rosa, A.; Cipriano, P.; Nedi, V.; Rossi, A.; Lombardi, G.; Colao, A.; Savastano, S.

In: Journal of Endocrinological Investigation, Vol. 34, No. 2, 02.2011, p. 90-96.

Research output: Contribution to journalArticle

Di Somma, C, Rivellese, A, Pizza, G, Patti, L, De Rosa, A, Cipriano, P, Nedi, V, Rossi, A, Lombardi, G, Colao, A & Savastano, S 2011, 'Effects of short-term treatment with orlistat on growth hormone/insulin-like growth factor-I axis in obese postmenopausal women', Journal of Endocrinological Investigation, vol. 34, no. 2, pp. 90-96.
Di Somma, C. ; Rivellese, A. ; Pizza, G. ; Patti, L. ; De Rosa, A. ; Cipriano, P. ; Nedi, V. ; Rossi, A. ; Lombardi, G. ; Colao, A. ; Savastano, S. / Effects of short-term treatment with orlistat on growth hormone/insulin-like growth factor-I axis in obese postmenopausal women. In: Journal of Endocrinological Investigation. 2011 ; Vol. 34, No. 2. pp. 90-96.
@article{6df9dea1a52344f491c271df26d6378e,
title = "Effects of short-term treatment with orlistat on growth hormone/insulin-like growth factor-I axis in obese postmenopausal women",
abstract = "Aim: Obesity is associated with an altered GH/IGF-I axis status, accounting for the increased cardiovascular risk in obese subjects with GH deficiency. Aim of this randomized, simple-blind, cross-over study was to verify the effectiveness of a short-term treatment with orlistat in reducing non-esterified fatty acid (NEFA) and influencing the endogenous activity of GH/IGF-I axis in obese subjects. Outcome measures: The primary outcome measures were post-prandial lipemia; GH peak after GHRH+arginine; IGF-I; IGF-binding protein (BP)-3, IGF-I/IGFBP-3 ratio. Secondary outcome measures were insulin resistance (IR) indexes (homeostasis model assessment of insulin resistance and Insulin Sensitivity Index). Study design: Twenty obese post-menopausal women (age: 53.6±6.2; body mass index: 34.1±4.0) were randomized to receive normo-caloric diet plus + orlistat (Roche, UK; 120 mg tid) or normo-caloric diet without the additional treatment. The duration of follow-up was 10 days for each treatment period. Results: Orlistat induced a weight-independent reduction in post-prandial NEFA levels compared with diet alone, with higher GH peak, IGF-I, and IGF-I/IGFBP3 ratio. GH peak was correlated negatively with postprandial NEFA and positively with IGF-I and IGF-4/IGFBP-3 ratio. Conclusions: Orlistat is effective in inducing a weight-independent high-er reduction in post-prandial NEFA levels than dietary treatment alone along with increase in GH peak, IGF-I levels, and IGF-I/IGFBP-3 ratio. These results might add a new potential benefit of orlistat in the management of obese subjects.",
keywords = "GH/IGHF-I axis, Insulin sensitivity, Obesity, Orlistat, Post-prandial lipid profile",
author = "{Di Somma}, C. and A. Rivellese and G. Pizza and L. Patti and {De Rosa}, A. and P. Cipriano and V. Nedi and A. Rossi and G. Lombardi and A. Colao and S. Savastano",
year = "2011",
month = "2",
language = "English",
volume = "34",
pages = "90--96",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "2",

}

TY - JOUR

T1 - Effects of short-term treatment with orlistat on growth hormone/insulin-like growth factor-I axis in obese postmenopausal women

AU - Di Somma, C.

AU - Rivellese, A.

AU - Pizza, G.

AU - Patti, L.

AU - De Rosa, A.

AU - Cipriano, P.

AU - Nedi, V.

AU - Rossi, A.

AU - Lombardi, G.

AU - Colao, A.

AU - Savastano, S.

PY - 2011/2

Y1 - 2011/2

N2 - Aim: Obesity is associated with an altered GH/IGF-I axis status, accounting for the increased cardiovascular risk in obese subjects with GH deficiency. Aim of this randomized, simple-blind, cross-over study was to verify the effectiveness of a short-term treatment with orlistat in reducing non-esterified fatty acid (NEFA) and influencing the endogenous activity of GH/IGF-I axis in obese subjects. Outcome measures: The primary outcome measures were post-prandial lipemia; GH peak after GHRH+arginine; IGF-I; IGF-binding protein (BP)-3, IGF-I/IGFBP-3 ratio. Secondary outcome measures were insulin resistance (IR) indexes (homeostasis model assessment of insulin resistance and Insulin Sensitivity Index). Study design: Twenty obese post-menopausal women (age: 53.6±6.2; body mass index: 34.1±4.0) were randomized to receive normo-caloric diet plus + orlistat (Roche, UK; 120 mg tid) or normo-caloric diet without the additional treatment. The duration of follow-up was 10 days for each treatment period. Results: Orlistat induced a weight-independent reduction in post-prandial NEFA levels compared with diet alone, with higher GH peak, IGF-I, and IGF-I/IGFBP3 ratio. GH peak was correlated negatively with postprandial NEFA and positively with IGF-I and IGF-4/IGFBP-3 ratio. Conclusions: Orlistat is effective in inducing a weight-independent high-er reduction in post-prandial NEFA levels than dietary treatment alone along with increase in GH peak, IGF-I levels, and IGF-I/IGFBP-3 ratio. These results might add a new potential benefit of orlistat in the management of obese subjects.

AB - Aim: Obesity is associated with an altered GH/IGF-I axis status, accounting for the increased cardiovascular risk in obese subjects with GH deficiency. Aim of this randomized, simple-blind, cross-over study was to verify the effectiveness of a short-term treatment with orlistat in reducing non-esterified fatty acid (NEFA) and influencing the endogenous activity of GH/IGF-I axis in obese subjects. Outcome measures: The primary outcome measures were post-prandial lipemia; GH peak after GHRH+arginine; IGF-I; IGF-binding protein (BP)-3, IGF-I/IGFBP-3 ratio. Secondary outcome measures were insulin resistance (IR) indexes (homeostasis model assessment of insulin resistance and Insulin Sensitivity Index). Study design: Twenty obese post-menopausal women (age: 53.6±6.2; body mass index: 34.1±4.0) were randomized to receive normo-caloric diet plus + orlistat (Roche, UK; 120 mg tid) or normo-caloric diet without the additional treatment. The duration of follow-up was 10 days for each treatment period. Results: Orlistat induced a weight-independent reduction in post-prandial NEFA levels compared with diet alone, with higher GH peak, IGF-I, and IGF-I/IGFBP3 ratio. GH peak was correlated negatively with postprandial NEFA and positively with IGF-I and IGF-4/IGFBP-3 ratio. Conclusions: Orlistat is effective in inducing a weight-independent high-er reduction in post-prandial NEFA levels than dietary treatment alone along with increase in GH peak, IGF-I levels, and IGF-I/IGFBP-3 ratio. These results might add a new potential benefit of orlistat in the management of obese subjects.

KW - GH/IGHF-I axis

KW - Insulin sensitivity

KW - Obesity

KW - Orlistat

KW - Post-prandial lipid profile

UR - http://www.scopus.com/inward/record.url?scp=79956344794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956344794&partnerID=8YFLogxK

M3 - Article

C2 - 21502796

AN - SCOPUS:79956344794

VL - 34

SP - 90

EP - 96

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 2

ER -